Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-07-01

Study Completion Date

2026-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to describe the real-world treatment patterns and clinical outcomes in moderate-to-severe AD patients receiving abrocitinib over a 12-month observation period, and to describe patient demographic and baseline characteristics.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

NCT06899204

Atopic Dermatitis Atopic Dermatitis, Unspecified Dermatitis, Atopic

NOT_YET_RECRUITING

A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India

NCT05375929

Atopic Dermatitis

COMPLETED PHASE3

A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

NCT05250115

Dermatitis, Atopic

TERMINATED

A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.

NCT05689151

Atopic Dermatitis Eczema

RECRUITING

Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

NCT04345367

Atopic Dermatitis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dermatitis, Atopic Dermatitis Eczema Skin Diseases Immune System Diseases Janus Kinase Inhibitors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients aged ≥12 years
2. Patients with confirmed diagnosis of moderate-to-severe AD as assessed by the physician
3. Patients for whom the physician's decision has been made to newly prescribe abrocitinib in usual clinical practice conditions
4. Evidence of a personally signed and dated informed consent/assent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study

Exclusion Criteria

Patients meeting any of the following criteria will not be included in the study:

1. Any prior use of abrocitinib
2. Simultaneous participation in a study that includes administration of any investigational drug or procedure

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No